PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Revenue declined and losses widened again, even as regulatory progress on a Herceptin biosimilar and expansion of arthritis and rare-disease drug pipelines continued in parallel.
2025 consolidated revenue fell 21.4% year-on-year to KRW 117.97bn, while the operating loss widened to KRW 95.57bn.
Net loss attributable to owners over the trailing four quarters (2025Q3-2026Q2) totaled about KRW 83.53bn, with the 2026Q2 loss the largest in that window.
The company disclosed that Herceptin biosimilar candidate AP063 has entered a regulatory pathway that could allow marketing application without an additional Phase 3 trial, following discussions with US and European regulators.
Degenerative arthritis candidate AP209 has submitted trial documents to Kyung Hee University Hospital's IRB, advancing toward the start of a domestic Phase 1 trial.
Subsidiary Apton has moved to advance a US Phase 3 trial and marketing application for GPC-100 (Burixafor), which has received FDA orphan drug designation.
Aprogen operates as a holding-company-type bio/pharma group spanning antibody biosimilar development, bio-CDMO services, and generic drug distribution.
Its core pipeline asset is Herceptin (trastuzumab) biosimilar candidate AP063, while a Remicade biosimilar reportedly gained marketing approval in Japan and Latin America and a Rituxan biosimilar is said to be preparing for Phase 1.
On the novel-drug side, the company is developing degenerative arthritis candidate AP209, built on a bispecific-receptor platform designed to bind growth factors.
The group includes subsidiaries with distinct business lines, including Aprogen Biologics for biologics manufacturing and CDMO, Aprogen Pharma for generic drug distribution, and Entotech, which makes semiconductor-process components.
KOSDAQ-listed subsidiary Apton holds global rights to hematopoietic stem cell mobilizer GPC-100 (Burixafor), and Apt Neuroscience, developing a Parkinson's disease therapy, is also part of the group.
The Osong manufacturing facility is described as featuring the world's largest perfusion-culture capacity for bulk antibody drug substance production, and the company is expanding CDMO sales efforts toward domestic and overseas pharmaceutical companies.
In the biosimilar and CDMO markets it competes against larger players such as Samsung Biologics and Celltrion, and a substantial portion of current revenue still comes from pre-commercial R&D, trial-run manufacturing, and generic drug distribution.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩24.2B | -₩23.9B | −98.9% |
| 2025Q3 | ₩35.6B | -₩22.3B | −62.7% |
| 2025Q4 | ₩31.5B | -₩26.9B | −85.4% |
| 2026Q1 | ₩36.3B | -₩20.6B | −56.8% |
| 2026Q2 | ₩35.5B | -₩22.4B | −63.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩78.3B | -₩119.3B | -₩98.7B | −152.3% | −45.9% | 30.1% |
| 2023 | ₩150.6B | -₩88.9B | -₩55.6B | −59.0% | −37.6% | 42.3% |
| 2024 | ₩150.1B | -₩86.8B | -₩58.1B | −57.8% | −36.6% | 38.6% |
| 2025 | ₩118B | -₩95.6B | -₩70.2B | −81.0% | −44.3% | 56.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue came to KRW 117.97bn, marking a double-digit decline after KRW 150.11bn in 2024 and KRW 150.58bn in 2023.
The operating loss widened to KRW 95.57bn from KRW 86.81bn in 2024, and the operating margin deteriorated to -81.0% from -57.8% in 2024 and -59.0% in 2023, reverting toward the deeply negative levels last seen at -152.3% in 2022.
Net loss attributable to owners reached KRW 70.20bn, larger than KRW 58.08bn in 2024 and KRW 55.62bn in 2023, though still smaller than the KRW 98.66bn loss in 2022.
Total equity rose modestly to KRW 458.61bn from KRW 440.09bn a year earlier, but the debt ratio climbed to 56.4% from 38.6% in 2024, 42.3% in 2023, and 30.1% in 2022, indicating a clear increase in leverage.
Operating cash flow was negative KRW 32.66bn, an improvement from negative KRW 44.99bn in 2024, negative KRW 58.16bn in 2023, and negative KRW 113.49bn in 2022, showing a gradually narrowing cash burn.
On a quarterly basis, revenue rose from KRW 24.16bn in 2025Q2 to KRW 35.55bn in 2025Q3 and KRW 36.29bn in 2026Q1 before easing slightly to KRW 35.53bn in 2026Q2.
Over the same period the operating loss ranged between roughly KRW 20.6bn and KRW 26.9bn per quarter, while the net loss attributable to owners widened from KRW 15.27bn in 2025Q2 to KRW 25.53bn in 2026Q2, the largest quarterly loss in the trailing four-quarter window.
The sum of net losses attributable to owners over the trailing four quarters (2025Q3-2026Q2) reached KRW 83.53bn, underscoring that the recent revenue pickup has not yet translated into an improved bottom line.
The global biosimilar market continues to expand as patents on originator antibody drugs expire, but major products such as Herceptin, Remicade, and Rituxan are already dominated by large biosimilar makers, requiring later entrants to pursue differentiated regulatory strategies or cost advantages.
Domestic CDMO competition is intensifying as Samsung Biologics, Celltrion, and Lotte Biologics continue large-scale capacity expansions, pushing smaller CDMO players to secure niche demand through specific culture technologies or responsive customer service.
Aprogen Biologics' Osong plant is described as differentiating itself from Fed-Batch-focused competitors by adopting a perfusion-culture approach.
In the rare-disease and hematopoietic stem cell mobilizer market, an approved competing drug already exists, positioning Apton's GPC-100 as a later entrant seeking to differentiate on factors such as speed of action.
South Korea's government has set a record national R&D budget for 2026, sustaining a policy environment supportive of biotech development.
Still, given the biosimilar, CDMO, and novel-drug development businesses all require large upfront investment and long commercialization timelines, pre-commercial companies in this space continue to face ongoing funding needs.
The company disclosed that both the European Medicines Agency and the US Food and Drug Administration indicated AP063 could be filed for approval without additional confirmatory Phase 3 data, though the EMA recommended, as a non-mandatory suggestion, additional dosing-response data in healthy adults.
The company said this recommendation is not a mandatory condition for filing, and the approval process is expected to proceed following submission of process performance qualification (PPQ) data.
For AP209, trial documents were submitted to Kyung Hee University Hospital's IRB in July 2026, and the company plans to negotiate participation with three additional university hospitals to run a Phase 1 trial across three to four institutions, enrolling 16 osteoarthritis patients for roughly 13 weeks to assess safety, pharmacokinetics, and early efficacy.
Subsidiary Apton announced in August 2026 plans to advance a US Phase 3 trial and marketing application for GPC-100, citing a precedent in which a similarly classed drug gained approval based on a single Phase 3 trial of 122 patients, and targeting clinical results within two years from a single trial of roughly 120 patients.
GPC-100 is described as eligible for FDA priority review benefits and seven years of orphan drug exclusivity following a US launch.
Whether each of these pipeline assets can successively clear its respective clinical and regulatory milestones will be a key variable for the company's future business trajectory, alongside whether non-bio businesses such as the semiconductor parts subsidiary can expand their revenue contribution.
The company has posted consecutive annual losses in recent years, making earnings-based valuation metrics difficult to derive, and the stock trades at a level below its book value per share.
Equity has grown modestly, but the debt ratio has risen in parallel, so book value alone warrants caution as a gauge of the share price level. Dividends have not been paid based on recent results, so dividend-related metrics currently carry limited relevance.
Multi-year results show revenue fluctuating and losses alternating between widening and narrowing, with no clear signal yet of a definitive turn toward profitability.
This financial structure means that the basis for future valuation assessments may continue to shift depending on how the clinical and regulatory progress of the drug and biosimilar pipeline unfolds.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Both the EMA and FDA reportedly indicated that AP063 could be filed for approval without an additional confirmatory Phase 3 trial. If this pathway is realized, it could structurally reduce both development cost and time to approval.
However, remaining procedural steps, including the EMA's recommendation for additional data, mean further confirmation is needed before an actual filing occurs.
Subsidiary Apton's GPC-100 has received FDA orphan drug designation, which the company says could bring priority review and seven years of market exclusivity. A precedent exists in which a similarly classed drug gained approval from a small single Phase 3 trial, suggesting a potentially shortened development timeline. The company also highlights faster onset of action as a differentiating feature.
Operating cash flow has steadily narrowed from negative KRW 113.49bn in 2022 to negative KRW 32.66bn in 2025. This suggests the pace of cash consumption has eased even amid continued losses. However, cash flow remains negative overall, so this should not be read as a complete turnaround.
2025 revenue fell 21.4% year-on-year while the operating loss widened, showing no clear sign of margin improvement. Net loss attributable to owners also grew larger than the prior year, marking a second consecutive year of expanding losses. Revenue has not yet translated into an improved bottom line.
The debt ratio has risen steadily from 30.1% in 2022 to 56.4% in 2025, indicating growing leverage as the company funds ongoing losses and investment through external financing. Should additional funding needs arise, the financial burden could increase further.
The 2026Q2 net loss attributable to owners reached KRW 25.53bn, the largest in the trailing four-quarter window. Revenue eased slightly from the prior quarter and the operating loss widened again. It still appears premature to conclude that losses have stabilized.
AP063 received a non-mandatory EMA recommendation for additional dosing-response data, and final approval will ultimately depend on the outcome of regulatory review. AP209 and GPC-100 are also at early clinical stages, and development timelines could be delayed if trial results fall short of expectations.
With multiple pipeline assets advancing simultaneously, the risk of clinical failure or delay for any individual asset remains present.
Persistent operating losses and negative operating cash flow over multiple years point to an ongoing need for external funding. With the debt ratio rising, any further capital raises or convertible bond issuances could dilute existing shareholders. If funding conditions were to deteriorate, pipeline development pace could also be affected.
The group includes numerous listed and unlisted affiliates such as Aprogen Biologics, Apton, and Apt Neuroscience, resulting in a complex web of equity relationships.
A disclosure noted that the controlling shareholder's stake in subsidiary Apton had decreased from a prior report, warranting ongoing monitoring of affiliate ownership changes. The impact of intra-group business and capital flows on the holding company's results is also worth watching.
Check whether preliminary Q3 2026 earnings are disclosed and whether revenue and profitability trends improve relative to Q2.
Monitor whether the AP209 domestic Phase 1 trial begins actual patient dosing and whether additional participating hospitals are confirmed.
Track whether AP063 advances to a formal EMA/FDA marketing application, including submission of process performance qualification data.
Check whether Apton's US Phase 3 trial for GPC-100 actually commences, including first patient enrollment.
Monitor whether the debt ratio rises further and whether new funding plans, such as capital raises or convertible bond issuances, are announced.
Aprogen saw 2025 revenue decline year-on-year while both the operating loss and net loss attributable to owners widened, and the trailing four-quarter window shows the loss trajectory at its widest point yet.
At the same time, the company is pursuing pipeline diversification, including regulatory progress on Herceptin biosimilar AP063, clinical entry for degenerative arthritis candidate AP209, and subsidiary Apton's push toward a US Phase 3 trial for GPC-100.
Equity has grown modestly, but the debt ratio has risen noticeably, pointing to increasing financial leverage, even as the operating cash outflow has gradually narrowed over multiple years.
Because earnings metrics remain persistently negative, traditional valuation measures carry inherent limitations, and the stock trades at a level below book value.
Key factors to watch going forward include the clinical and regulatory progress of each pipeline asset, any resulting need for further capital raises, and whether non-bio businesses such as semiconductor components expand their revenue contribution.
This report is provided for informational purposes only and does not present an investment opinion or target price.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.